Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 29.4% on Saturday . The company traded as high as C$0.11 and last traded at C$0.11. 602,760 shares were traded during mid-day trading, an increase of 511% from the average session volume of 98,700 shares. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The firm has a market capitalization of C$20.73 million, a P/E ratio of -4.07 and a beta of 1.25. The company’s 50 day moving average price is C$0.09 and its 200 day moving average price is C$0.10.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
See Also
- Five stocks we like better than Hemostemix
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
